Estimation Risks Related to Inventory Valuation and Revisions to Redemption Prices
First written in FY2021. 9 of 10 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2018: 10 of 37 companies on the "Worse" side.
34 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「Judgments regarding impairment of goodwill and technology assets take into account the management environment and business plans at the relevant time. If the key assumptions underlying the business plans require revision, this could have a material impact on the valuation of goodwill and technology assets in the consolidated financial statements for the following consolidated fiscal year.」
The Company continues to identify estimation risk arising from changes in business plans and the management environment affecting accounting valuations. - FY2024-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The Company reconfirmed, through a comprehensive statement, that no new events or material changes had arisen in the estimation risks related to inventory valuation and revisions to reimbursement prices and other matters. - FY2024-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The Company reconfirmed, through a comprehensive statement, that there were no material changes in the estimation risks related to inventory valuation and revisions to reimbursement prices and other matters. - FY2023-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no material changes in the accounting estimates concerning the impact of COVID-19 on the Group.」
The company has reconfirmed that there have been no material changes to the accounting estimates related to the impact of COVID-19. - FY2023-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no material changes in the accounting estimates concerning the impact of COVID-19 on the Group.」
The company has reconfirmed that there have been no material changes to the accounting estimates related to the impact of COVID-19. - FY2023-Q1RestatedAnnual report
「During the cumulative first quarter of the current consolidated fiscal year, there were no material changes in the accounting estimates concerning the impact of COVID-19 on the Group.」
The company has reconfirmed that there have been no material changes to the accounting estimates related to the impact of COVID-19. - FY2022RestatedAnnual report
「If the net realizable value, a key assumption, declines significantly due to factors including changes in the future economic environment and the effects of healthcare system reforms, including revisions to reimbursement prices, this could have a material impact on judgments concerning inventory valuation.」
The Company continues to identify estimation risk arising from the impact of inventory net realizable value and healthcare system reforms, including revisions to reimbursement prices, on valuation judgments. - FY2022-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no material changes in the accounting estimates concerning the impact of COVID-19 on the Group.」
The Company reconfirmed that there were no material changes in the accounting estimates concerning the impact of COVID-19. - FY2022-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no material changes in the accounting estimates concerning the impact of COVID-19 on the Group.」
The Company reconfirmed that there were no material changes in the accounting estimates concerning the impact of COVID-19. - FY2021First statedAnnual report
「Amounts recorded in the consolidated financial statements for the fiscal year: inventory valuation losses included in cost of sales, ¥22.656 million; inventories, ¥3,699.527 million. If the net realizable value, a key assumption, declines significantly due to factors including changes in the future economic environment and the effects of healthcare system reforms, including revisions to reimbursement prices, this could have a material impact on judgments concerning inventory valuation.」
The Company recorded inventory valuation losses and an inventory balance, and newly explicitly identified the risk that declines in net realizable value and revisions to reimbursement prices could affect future valuation judgments.